<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lecouturier J</submitter><funding>National Institute for Health Research (NIHR)</funding><pagination>e0265048</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8979436</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(4)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>Cutaneous melanoma rates are steadily increasing. Up to 20% of patients diagnosed with AJCC Stage I/II melanomas will develop metastatic disease. To date there are no consistently reliable means to accurately identify truly high versus low-risk patient subpopulations. There is hence an urgent need for more accurate prediction of prognosis to determine appropriate clinical management. Validation of a novel prognostic test based on the immunohistochemical expression of two protein biomarkers in the epidermal microenvironment of primary melanomas was undertaken; loss of these biomarkers had previously been shown to be associated with a higher risk of recurrence or metastasis. A parallel qualitative study exploring secondary care health professional and patient views of the </pubmed_abstract><journal>PloS one</journal><pubmed_title>Health professional and patient views of a novel prognostic test for melanoma: A theoretically informed qualitative study.</pubmed_title><pmcid>PMC8979436</pmcid><funding_grant_id>II-LA-0417-20001</funding_grant_id><pubmed_authors>Lecouturier J</pubmed_authors><pubmed_authors>Labus M</pubmed_authors><pubmed_authors>Ellis RA</pubmed_authors><pubmed_authors>Lovat PE</pubmed_authors><pubmed_authors>Bosomworth H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Health professional and patient views of a novel prognostic test for melanoma: A theoretically informed qualitative study.</name><description>&lt;h4>Objectives&lt;/h4>Cutaneous melanoma rates are steadily increasing. Up to 20% of patients diagnosed with AJCC Stage I/II melanomas will develop metastatic disease. To date there are no consistently reliable means to accurately identify truly high versus low-risk patient subpopulations. There is hence an urgent need for more accurate prediction of prognosis to determine appropriate clinical management. Validation of a novel prognostic test based on the immunohistochemical expression of two protein biomarkers in the epidermal microenvironment of primary melanomas was undertaken; loss of these biomarkers had previously been shown to be associated with a higher risk of recurrence or metastasis. A parallel qualitative study exploring secondary care health professional and patient views of the </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-05T15:52:55.27Z</modification><creation>2025-04-05T15:52:55.27Z</creation></dates><accession>S-EPMC8979436</accession><cross_references><pubmed>35377887</pubmed><doi>10.1371/journal.pone.0265048</doi></cross_references></HashMap>